ATLAS METABOLIC, DESCRIBED BY ATLAS: WHAT THE BUILD INCLUDES AND WHO IT DOES NOT SUITThis is not a review — it is a disclosed first-party overview of what Atlas Metabolic licenses, written to be checkable rather than flattering.

Educational overview · Approx. 10 min read · illustrative, not advice

This is not a review — it is a disclosed first-party overview of what Atlas Metabolic licenses, written to be checkable rather than flattering.

Disclosure first: who wrote this, and what it is not

This page is published by Atlas Metabolic about Atlas Metabolic. Everyone who wrote it is affiliated with the company. It is not a review, it is not independent, and it is not neutral — it is the vendor describing its own offering, and you should read it with exactly that discount applied.

We are stating that plainly at the top because the alternative is illegal. The FTC's Rule on the Use of Consumer Reviews and Testimonials — 16 CFR Part 465, published 22 August 2024 and effective 21 October 2024 — prohibits fake and false reviews and prohibits insider reviews and testimonials that do not clearly disclose the writer's material connection to the business. A company page dressed up as an impartial verdict on that company is the exact thing the rule was written to stop. So this is not a verdict. It is a specification.

If what you actually want is independent opinion, do not take it from us. Ask on the fit call for partner references you can speak to directly, without us on the line. — this slot must be filled only with named, written-consent, verifiable statements from real partners, with the material connection disclosed; until such consent exists, it stays empty rather than being filled with anything composed.

What Atlas Metabolic actually is

Atlas Metabolic licenses a complete, white-label metabolic health business build to a partner. You get the operating system for a cash-pay metabolic wellness business under your own brand: the telehealth stack, the ordering system, member AI coaching, the brand kit and the operational playbooks. You run it. You own the brand. You keep the revenue.

The commercial shape is a one-time license fee, 0% of revenue, and no ongoing partner fees. The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own.. There is no royalty, no percentage of collections, no required monthly platform charge. That structure is the whole argument, and the reason it matters compounds over years rather than months — the arithmetic of why is laid out in the explanation of what a royalty really costs and, more bluntly, in the walkthrough of how a gross royalty actually compounds against you.

Two boundaries that never move. First, Atlas provides no medical services and employs no clinicians. Clinical care sits with a separately licensed medical entity, and clinical judgment belongs to licensed clinicians, permanently. Second, Atlas is not a franchise and does not present itself as one; the structural differences — and the things a license genuinely does not give you that a franchise would — are set out in the comparison of franchise versus license.

What the build includes, component by component

A build is the delivery event: the point at which the assembled system is handed over and made yours. Here is what is inside it. Where a specification is not yet fixed, it is marked rather than guessed.

• Telehealth stack — the member-facing technology for intake, scheduling, consent capture and visit delivery, configured to your brand and connected to your CRM rather than sitting beside it. Ask Atlas to put this in writing: named platform components and hosting arrangement.
• Ordering system — the fulfilment and logistics layer: catalogue, order capture, status, and the flow of information between the ordering side and the separately licensed medical entity. Ask Atlas to put this in writing: fulfilment partners and shipping coverage.
• Member AI coaching — the between-visit layer that carries a member through the program: structured education, adherence support and check-ins. It is a wellness tool. It does not provide medical advice, does not diagnose, and does not substitute for a clinician.
• Brand kit — name development support, identity system, site, page templates and the full asset set, built so the brand is yours and stays yours if you and Atlas ever part company. The reason that matters is covered in the piece on owning your brand.
• Operational playbooks — written procedures for enrollment, member communication, escalation, staffing and the daily running of the operation, with the sequencing already worked out rather than left as an exercise.
• Build support through go-live, with a defined scope and a defined end. Ask Atlas to put this in writing: build duration and post-build support terms.
• Compliance architecture documentation — the structural map of how the non-clinical and clinical sides separate, written so your counsel can review it. It is input to your lawyer, not a replacement for one. The framing is described further on the compliance page.

What the license fee does not cover

This is the section most vendor pages skip, which is why we put it above the persuasion rather than below it. The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own. covers the build. It does not cover the costs that are structurally yours and always will be.

Your entity formation. Your counsel — and you will need counsel, in your state, more than once. Your professional licensure and any controlled-substance or DEA registration, currently $888 per three-year practitioner term under 21 CFR 1301.13. Your professional liability cover, in a market where premiums have risen for a seventh consecutive year and the share of premiums increasing year over year climbed from 13.7% in 2018 to nearly 40% in 2025. Your merchant processing. Your working capital. Ask Atlas to put this in writing: whether any media budget is included in the build.

If you want the full inventory of what an operator carries regardless of who builds the system, the GLP-1 clinic startup checklist is the unglamorous version, and we would rather you read it before you talk to us than after.

Why the price is not on this page

The license fee is not published, and that is a design decision rather than a sales tactic. A number without the scope attached to it is noise — it invites comparison against offerings that include different things, exclude different things and carry different ongoing obligations, and the comparison produces a wrong answer in both directions.

The fee is disclosed in full on the fit call, in writing, with what it covers itemised, before anything is signed. Nobody is asked to commit to a number they have not seen broken down. If a company will not tell you the price at the point where you can evaluate it against scope, that is a problem; if a company posts a number with no scope, that is a different problem. We would rather have the second conversation.

The license fee is one-time. It carries 0% of revenue and no ongoing partner fees. The figure is not published anywhere, by design — it is disclosed in full on the fit call, where it can be put next to what it covers instead of floating on its own.

Why there are no income figures anywhere on this site

You will not find a revenue projection, a margin, a break-even timeline, an ROI figure or a hypothetical profit-and-loss statement on any Atlas page. Not a range, not an illustration, not a labelled example. This is not modesty and it is not a lack of data.

A franchisor may make financial performance representations only inside a Franchise Disclosure Document, under a specific regulatory regime, with substantiation on file. Atlas has no FDD, because Atlas is not selling a franchise. An income figure published outside that regime is unsubstantiated by definition, and it is exactly the artefact that turns an opportunity page into a regulatory exposure — for us, and eventually for the person who relied on it.

So the operating rule is simple: the numbers we publish are public market and cost data, never predictions about you. Category data is real — Morgan Stanley Research projects global GLP-1 sales across diabetes and obesity at approximately $190 billion by 2035, Goldman Sachs Research forecasts the anti-obesity drug market at approximately $95 billion by 2030 after revising down from approximately $130 billion, and 18% of US adults report having ever used a GLP-1 drug with 12% currently using one. None of that tells you what a business you run will do, and we will not pretend it does. If you want the discipline of thinking about the cost side without being handed fantasy revenue, the piece on unit economics for metabolic care does exactly that.

Judge us on the restraint. Anyone showing you an earnings number without an FDD is telling you something important about themselves.

Who this does not suit

Genuinely, several kinds of buyer should not do this, and finding that out on the fit call costs everyone less than finding it out afterwards.

• Anyone looking for passive income. This is an operating business. It requires an operator, a staffing decision and daily attention. Nothing about a build makes it run itself.
• Anyone unwilling to retain and pay their own counsel. Structure, licensure and the separation between clinical and non-clinical functions have to be reviewed by a lawyer in your state. If that expense reads to you as optional, this is the wrong offering.
• Anyone who needs franchise financeability. Franchise-backed lending pathways, including certain SBA routes tied to the SBA Franchise Directory, generally do not apply to a license that is not a franchise. That is a real disadvantage of the structure and we are not going to argue you out of it.
• Anyone who wants a protected territory. Franchises sell exclusive territory; Atlas does not. A partner operates in a market without a contractual promise that Atlas will never license another partner nearby. If territorial exclusivity is your central requirement, buy a franchise instead — and read the fine print on what the exclusivity actually covers. How Atlas thinks about additional markets is described on the expansion path page.
• Anyone who wants Atlas to supply clinicians. We do not have any. Ever. Clinical care sits with a separately licensed medical entity that you engage.
• Anyone who wants a guarantee. There is none, of outcome, of revenue, or of member results.
• Anyone who wants to skip the compliance work. The offering is designed around it, and a partner determined to route around it is a partner we cannot help.

What Atlas does not have yet

We do not have a decades-long track record. Ask Atlas to put this in writing: founding year and number of completed partner builds to date. If your diligence standard is a twenty-year operating history with hundreds of units, we do not meet it today, and no amount of design work changes that fact.

We do not have an FDD, which means we cannot lawfully give you the substantiated financial performance representations a mature franchisor can. You get structure, scope and references instead of numbers.

We do not have SBA or franchise-directory financeability, for the reason above.

We do not have third-party audited member outcome data. Any efficacy question about any medication or supplement belongs to the clinicians and the manufacturers, not to us, and we make no efficacy claims about any product.

We do not have a long public review history. That is precisely why this page discloses its own authorship rather than manufacturing one. The correct response to a thin review record is references you can call, not reviews we could have written.

What we do have is a structure we will explain line by line, a scope document we will hand to your lawyer, and a willingness to say no. The diligence page tells you what to demand from us, and the due diligence checklist tells you what to demand from anyone selling a build — including questions we would rather you not ask us casually.

The fit call, and how to get one

Atlas takes a limited number of partner builds (Ask Atlas to put this in writing: partner slots per quarter). The constraint is build capacity, not scarcity theatre, and it means the fit call has to work in both directions: you are deciding whether the structure suits you, and we are deciding whether we can actually deliver for you. A meaningful share of these conversations end with us declining, usually because the person wants passive income, wants a guarantee, or wants a territory.

On the call you get the full fee disclosure in writing with scope itemised, the build scope document, the compliance architecture for your counsel to review, and partner references to contact without us present. You are not asked to decide on the call. Nobody who needs a decision that fast is being served well by one.

If you have read this far and the honest version has not put you off — the disclosed authorship, the absent price, the missing income figures, the list of things we do not have — then the application is the next step. It is a qualification form, not a purchase. Start there, and bring your hardest question. If you want the mechanics of the build itself before you apply, how Atlas works covers the sequence end to end.

FREQUENTLY ASKED QUESTIONS.